Go to content
UR Home

Predictive value of PD-L1 based on mRNA level in the treatment of stage IV melanoma with ipilimumab

Brüggemann, C. ; Kirchberger, M. C. ; Goldinger, S. M. ; Weide, B. ; Konrad, A. ; Erdmann, M. ; Schadendorf, D. ; Croner, R. S. ; Krähenbühl, L. ; Kähler, K. C. ; Hafner, C. ; Leisgang, W. ; Kiesewetter, F. ; Dummer, R. ; Schuler, G. ; Stürzl, M. ; Heinzerling, L.


Introduction PD-L1 is established as a predictive marker for therapy of non-small cell lung cancer with pembrolizumab. Furthermore, PD-L1 positive melanoma has shown more favorable outcomes when treated with anti-PD1 antibodies and dacarbazine compared to PD-L1 negative melanoma. However, the role of PD-L1 expression with regard to response to checkpoint inhibition with anti-CTLA-4 is not clear, ...


Owner only: item control page
  1. Homepage UR

University Library

Publication Server


Publishing: oa@ur.de
0941 943 -4239 or -69394

Dissertations: dissertationen@ur.de
0941 943 -3904

Research data: daten@ur.de
0941 943 -5707

Contact persons